8-K - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

424B5 - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

EFFECT - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

424B3 - Imunon, Inc. (0000749647) (Filer)

DEF 14A - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three months ended March 31, 2025 and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian can

LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 12, 2025 to discuss financial results for the first quarter ended March 31, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing the IMNN-001 development program toward initiation of a Phase 3 clinical trial in advanced ovarian cancer. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesday, March 25, 2025, at 2:00 p.m. ET LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of its lead candidate IMNN-001 in development for the treatment

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer  Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 2025 Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent business updates including progress in advancing the IMNN-001 development program toward initiation of a Phase 3 clinical trial in advanced ovarian cancer. "2024 was a piv

LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will report full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The Company will host a conference call that same day beginning at 11:00 a.m. ET to discuss the results and provide a general business update. To participate in the call, please dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON 2024 Earnings Call. A live webcast of the call will also be available here. The call will

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pat

LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technolo

Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient population compared with the standard-of-care control armOS was extended by 15.7 months in patients receiving three or more doses of IMNN-001 in the 17-dose protocol Patients also receiving maintenance PARP inhibitor therapy demonstrated an OS hazard ratio of 0.41 in the IMNN-001 trial arm with median OS not yet reached at the time of data lockRobust and durable benefit of IMNN-001 observed in OS supported by a three-month improvement in the primary endpoint of progression-free survival (PFS)IMU

Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will issue a news release announcing topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer tomorrow, July 30, at approximately 8:00 a.m. Eastern time, and will host an investment community conference call to discuss the results and answer questions at 8:30 a.m. Eastern time. IMNN-001 is the Company's interleukin-12 (IL-12) immunotherapy based on its TheraPlas™ technology.

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the three months ended March 31, 2024. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for first-line treatment of locally advanced ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery techno

3 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at a ratio of one (1) share of common stock for every fifteen (15) shares of common stock, that will become effective as of 12:01 a.m. (Eastern Time) on July 25, 2025 (the "Effective Date"). The Company's common stock will begin trading on a split-adjusted basis when the market opens on July 25, 2025. At the Company's Annual Meeting of Stockholders held on July 11, 2025, the Company's stockholders approved a proposal to

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Nasdaq Hearing Panel has granted its request for an exception to complete its compliance plan, allowing the Company to maintain its listing on the Nasdaq Stock Market. Following a comprehensive review of IMUNON's strategies to regain compliance, the Nasdaq Hearing Panel stated that IMUNON has already achieved compliance with the Equity Rule through recent fundraising activities. To ensure sustained

LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stock Market LLC (Nasdaq), it has submitted its plan to Nasdaq to regain compliance with the minimum bid price requirement and the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. On May 29, 2025, the Company requested a hearing before The Nasdaq Hearings Panel ("Panel"). At this hearing, the Company will request an extension to meet the requirements and return to compliance. In an exchange with Nasdaq, the Company has established

ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of action, producing IL-12 and key anti-cancer immune cytokines in the tumor-microenvironment post-treatment Company currently advancing Phase 3 pivotal trial of IMNN-001, with first two sites initiated LAWRENCEVILLE, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced the presentation of new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigati

Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital LAWRENCEVILLE, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced that an abstract highlighting Phase 1 proof-of-concept clinical trial results of IMNN-101, an investigational DNA plasmid vaccine based on the Company's proprietary PlaCCine®

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of Imunon, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, June 12, 2025, at 11:30 a.m. ET. Pre-register for Imunon's virtual presentation at the Virtual Investor Conferences site HERE. This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and BRCA2 mutations LAWRENCEVILLE, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced positive data from the Company's Phase 2 OVATION 2 Study showing that treatment with IMNN-001 in women with newly diagnose

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously announced sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) and short-term warrants to purchase up to an aggregate of 14,444,446 shares of common stock at a purchase price of $0.45 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants in a private placement priced at-th

Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON's FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company's scientific advisory board. Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute. He joins current scientific advisory board members Dan H. Bar

SC 13G - Imunon, Inc. (0000749647) (Subject)

SC 13G/A - Imunon, Inc. (0000749647) (Subject)

SC 13G - Imunon, Inc. (0000749647) (Subject)